Siena

• A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without ext … Recruiting
  2022-502877-41-01 9 2025-02-10 Pulmonary sarcoidosis with or without extrapulmonary manifestations
• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting
  2023-504022-19-01 5 2024-12-13 Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
• A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting
  2022-500455-23-00 5 2024-12-11 Candidemia
• A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined … Recruiting
  2024-518891-29-00 4 2024-11-18 MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy
• A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe … Recruiting
  2023-508517-16-00 7 2024-11-10 Advanced Solid Tumors with a KRAS p.G12C Mutation
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 10 2024-10-09 HLA-A2 negative metastatic uveal melanoma
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• Trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant a … Recruiting
  2023-504169-22-02 5 2024-07-31 Severe cardiac inflammation
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 Cholangiocarcinoma (LTT, 26.0)
• Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroi … Recruiting
  2023-504756-96-00 5 2024-03-22 Recurrent pericarditis, idiopathic or secondary to invasive cardiac pr
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• A study to test how effective belumosudil tablets are for treating adult participants with chronic lung allograft dysfunction Recruiting
  2023-503462-23-00 5 2023-12-28 Lung transplant rejection
• Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meR … Recruiting
  2022-500988-12-00 4 2023-12-18 Advanced, naïve, Merkel cell carcinomas
• Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting
  2022-502775-29-01 5 2023-12-14 Early stage Follicular Lymphoma
• 24 weeks double-blind randomized placebo-controlled trial to evaluate efficacy, PK, safety of LOU064 in adolescents (12 - <18) with CSU and … Recruiting
  2022-502159-78-00 5 2023-12-06 Chronic Spontaneous Urticaria
• Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled, clinical trial, on the efficacy and tolerability of d … Recruiting
  2024-511961-12-00 10 2023-10-12 Knee osteoarthritis
• Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting
  2022-502732-39-00 10 2023-09-01 Previously treated non-ocular advanced melanoma
• A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients … Recruiting
  2022-501822-39-00 9 2023-07-31 Glioblastoma
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl- … Recruiting
  2023-510431-11-00 4 2023-07-21 Chronic Lymphocytic Leukemia
• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIA … Recruiting
  2022-501894-37-00 4 2023-03-02 prostate cancer
• VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM … Recruiting
  2024-520119-41-00 4 2023-01-15 Previously untreated patients with diagnosis of HCL

Showing 73–96 of 228 trials